We have placed cookies on your computer to help make this website better. We use a PIWIK Analytics script which sets performance cookies. More details and information can be found in our cookie policy. Please refer to the privacy statement to adjust your settings for the website analytics tracking by PIWIK (e.g. deny use/opt-out). More info

Confirm

News & Press Releases

News

August 10, 2018
Grünenthal has proven its quality for medical devices: Our quality management system has been certified against the important industry standard DIN EN ISO 13485:2016. It confirms that we fulfil the requirement to manufacture medical devices and sell them in Europe. Another major step forward to strengthen our capabilities for Contract Manufacturing Business customers.

July 23, 2018
Grünenthal is setting a new standard in global demand and supply planning capabilities. We have just implemented a new IT solution, SAP Integrated Business Planning, to support the end-to-end IBP process and provide precise and adaptive planning possibilities, automation and seamless data integration. Another major step forward to strengthen our delivery reliability for our Contract Manufacturing Business customers.

June 29, 2018
Today our colleagues in Switzerland celebrate a major milestone: For 25 years they are producing Tramadol in Mitlödi for the global market – this is the world’s largest production unit for Tramadol Hydrochloride. We operate an API-production in top quality: well trained workforce, state of the art facility, precisely controlled processes and efficient Equipment.
Read more (Press release only available in German)

May 23, 2018
TECNANDINA, our Manufacturing Site in Ecuador, was honored from Novartis Ecuador with the annual award “Best Logistic Service Supplier in the Andean Cluster”.
Read more: www.tecnandina.com

February 2018
Interview in World Pharmaceutical Frontiers

1/12/2017

Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America.

12/14/2016

Quito, Ecuador and Aachen, Germany. December 14, 2016. The Grünenthal Group announces today that its manufacturing site in Ecuador, Tecnandina, successfully passed the inspection to manufacture in accordance with the European GMP regulations. The certification covers the production of solid and semi-solid pharmaceuticals for the third time and now, for the first time, also liquid pharmaceuticals. This GMP Certificate will be valid for another three years.

10/1/2015

Quito, Ecuador and Aachen, Germany. October 1, 2015. The Grünenthal Group announces that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária, Brazilian Health Surveillance Agency). This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification.